The biologic basis for the use of retinoids in cancer prevention and treatment

Current Opinion in Oncology

Volumn 11, Issue 6, 1999, Pages 497-502

  Kurie, Jonathan M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; ALPHA INTERFERON; BEXAROTENE; GRANULOCYTE COLONY STIMULATING FACTOR; POLYPRENOIC ACID; RETINAMIDE II; RETINOID; RETINOL; TAMOXIFEN; UNCLASSIFIED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; BREAST CANCER; CANCER; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; DRUG MECHANISM; FEVER; HEART FAILURE; HUMAN; HYPOTENSION; KAPOSI SARCOMA; KIDNEY FAILURE; LIVER CELL CARCINOMA; LUNG CANCER; LUNG HEMORRHAGE; LUNG INFILTRATE; MYELODYSPLASTIC SYNDROME; PERICARDIAL EFFUSION; PLEURA EFFUSION; PRIORITY JOURNAL; RESPIRATORY DISTRESS; RETINOIC ACID SYNDROME; REVIEW; SIDE EFFECT; SKIN CANCER; THYROID CANCER; UTERINE CERVIX CANCER; WEIGHT GAIN;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; RETINOIDS;

EID: 0032700248     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199911000-00011     Document Type: Review

References (62)

1. 1 Mangelsdorf DJ, Umesono K, Evans RM: The retinoid receptors. In The Retinoids: Biology, Chemistry, and Medicine, edn 2. Edited by Sporn MB, Roberts AB, Goodman DS. Philadelphia: Lippincott-Raven; 1994:319-348. This is a complete review of retinoid receptors, their function, and their importance in cell growth and differentiation.
2. 2 Slack JL: The biology and treatment of acute progranulocytic leukemia. Curr Opin Oncol 1999, 11:9-13.
3. 3 He LZ, Tribioli C, Rivi R, Peruzzi D, Pelicci PG, Scares V, et al.: Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. Proc Natl Acad Sci U S A 1997, 94:5302-5307.
4. 4 Lotan R, Xu XC, Lippman SM, Ro JY, Lee JS, Lee JJ, Hong WK: Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med 1995,332:1405-1410.
5. 5 Xu XC, Sneige N, Liu X, Nandagiri R, Lee JJ, Lukmanji F, et al.: Progressive decrease in nuclear retinoic acid receptor beta messenger RNA level during breast carcinogenesis. Cancer Res 1997, 57:4992-4996.
6. 6 Xu XC, Lee JS, Lee JJ, Hong WK, Lotan R: Decreased expression of retinoic acid receptor B in bronchial mucosa from heavy smokers and its up-regulation during chemoprevention trial with 13-cis retinoic acid [abstract]. Proc Amer Assoc Cancer Res 1997, 38:528.
7. 7 Gudas LJ, Sporn MB, Roberts AB: Cellular biology and biochemistry of the retinoids. In The Retinoids: Biology, Chemistry, and Medicine, edn 2. Edited by Sporn MB, Roberts AB, Goodman DS. Philadelphia: Lippincott-Raven; 1994:443-520.
8. 8 Moon RC, Mehta RG, Rao KVN: Retinoids and cancer in experimental animals. In The Retinoids: Biology, Chemistry, and Medicine, edn 2. Edited by Sporn MB, Roberts AB, Goodman DS. Philadelphia: Lippincott-Raven; 1994:573-595.
9. 9 Muto Y, Moriwaki H, Ninomiya M, Saito AS, Takasaki KT, Tanaka T, et al.: Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 1996, 334:1561-1567. This is a landmark study demonstrating the activity of a novel retinoid in the prevention of hepatocellular carcinoma.
10. 10 Muto Y, Moriwaki H, Saito A: Prevention of second primary tumors by an acyclic retinoid, in patients with hepatocellular carcinoma. N Engl J Med 1999, 340:1046-1047. This is a follow-up to study of patients enrolled on the trial in reference 9 (Muto et al., N Engl J Med 1996, 334:1561-1567), demonstrating a survival advantage in patients treated with the retinoid.
11. 10 Muto Y, Moriwaki H, Saito A: Prevention of second primary tumors by an acyclic retinoid, in patients with hepatocellular carcinoma. N Engl J Med 1999, 340:1046-1047. This is a follow-up to study of patients enrolled on the trial in reference 9 (Muto et al., N Engl J Med 1996, 334:1561-1567), demonstrating a survival advantage in patients treated with the retinoid.
12. 11 Moon TE, Levine N, Cartmel B, Bangert JL: Retinoids in prevention of skin cancer. Cancer Lett 1997, 114:203-205.
13. 12 Stam-Posthuma JJ, Vink J, le Cessie S, Bruijn JA, Bergman W, Pavel S: Effect of topical tretinoin under occlusion on atypical naevi. Melanoma Res 1998, 8:539-548.
14. 13 Zhang S, Hunter DJ, Forman MR, Rosner BA, Speizer FE, Colditz GA, et al.: Dietary carotenoids and vitamins A, C, and E and risk of breast cancer. J Natl Cancer Inst 1999, 91:547-556.
15. 14 Torrisi R, Parodi S, Fontana V, Pensa F, Casella C, Barreca A, et al.: Effect of fenretinide on plasma IGF-1 and IGFBP-3 in early breast cancer patients. Intl J Cancer 1998, 76:787-790.
16. 15 Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al.: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998, 279:563-566.
17. 16 Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X: Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 1999, 91:151-156.
18. 17 Hong WK, Sporn MB: Recent advances in chemoprevention of cancer. Science 1997, 278:1073-1077. An excellent review of retinoids and other agents in cancer chemoprevention.
19. 18 Zandwijk NV, Pastorino U, De Vries N, H Van Tinteren: Randomized trial of chemoprevention with Vitamin A and N-acetylcysteine in patients with cancer of the upper and lower airways: the Euroscan study [abstract]. Proc Am Soc Clin Oncol 1999, 35:464a.
20. 19 Heinonen OP, Albanes D: The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994, 330:1029-1035.
21. 20 Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, et al.: Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996, 334:1145-1149.
22. 21 Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al.: Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996, 34:1150-1155.
23. 22 Halpern MT, Gillespie BW, Warner KE: Patterns of absolute risk of lung cancer mortality in former smokers. J Natl Cancer Inst 1993, 85:457-464.
24. 23 Lubin JH, Blot WJ: Lung cancer and smoking cessation: patterns of risk. J Natl Cancer Inst 1993, 85:422-423.
25. 24 Sobue T, Yamaguchi N, Suzuki T, Fujimoto I, Matsuda M, Doi O, et al.: Lung cancer incidence rate for male ex-smokers according to age at cessation of smoking. Jpn J Cancer Res 1993, 84:601-607.
26. 25 Ruidi C, Aihua D, Peiyu B, Zhongru G, Huazao L, Shifeng S, et al.: Chemoprevention of cancer of uterine cervix: a study on chemoprevention of retinamide II from cervical precancerous lesions. J Cell Biochem Suppl 1997, 28-29:140-143.
27. 26 Jessop D: Retinoids promising in Kaposi's sarcoma trials [letter]. Lancet 1998, 351:1185. A landmark study demonstrating activity of retinoids in the treatment of Kaposi's sarcoma.
28. 27 Soignet S, Fleischauer A, Polyak T, Heller G, Warrell RP Jr: All-trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: long-term follow-up of the New York study. Cancer Chemother Pharmacol 1997, 40(suppl):S25-S29.
29. 28 Soignet SL, Benedetti F, Fleischauer A, Parker BA, Truglia JA, Ra Crisp M, Warrell RP Jr: Clinical study of 9-cis retinoic acid (LGD1057) in acute promyelocytic leukemia. Leukemia 1998, 12:1518-1521.
30. 29 Menell JS, Cesarman GM, Jacovina AT, McLaughlin MA, Lev EA, Hajjar KA: Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999, 340:994-1004.
31. 30 DeBotton S, Dombret H, Sanz M, San Miguel J, Caillot D, Zittoun R, et al.: Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. Blood 1998, 92:2712-2718.
32. 31 Nicolls MR, Terada LS, Tuder RM, Prindiville SA, Schwarz MI: Diffuse aleveolar hemorrhage with underlying pulmonary capillaritis in the retinoic acid syndrome. Am J Respir Crit Care Med 1998, 158:1302-1305.
33. 32 Torromeo C, Latagliata R, Avvisati G, Petti MC, Mandelli F: Coronaric thrombotic events in acute promyelocytic leukemia during all-trans retinoic acid treatment: a role for adhesion molecules overexpression? Leukemia 1999, 13:312-313.
34. 33 Ding W, Li Y-P, Nobile LM, Grills G, Carrera I, Paietta E, et al.: Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARα fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy. Blood 1998, 92:1172-1183.
35. 34 Imaizumi M, Suzuki H, Yoshinari M, Sato A, Saito T, Sugawara A, et al.: Mutations in the E-domain of RARα portion of the PML/RARα chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia. Blood 1998, 92:374-382.
36. 35 Warrell RP Jr, He L-Z, Richon V, Calleja E, Pandolfi PP: Therapeutic targeting of transciption in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 1998, 90:1621-1625.
37. 36 Bergstrom SK, Gillan E, Quinn JJ, Altman AJ: Arsenic trioxide in the treatment of a patient with multiply recurrent, ATRA-resistant promyelocytic leukemia: a case report. J Pediatr Hematol Oncol 1998, 20:545-547.
38. 37 Hofmann WK, Ganser A, Seipelt G, Ottman OG, Zander C, GeiBler G, et al.: Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor. Ann Hematol 1999, 78:125-130.
39. 38 Estey EH, Thall PF, Pierce S, Cortes J, Beran M, Kantarjian H, et al.: Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin + all-trans retinoic acid + granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 1999, 93:2478-2484.
40. 39 Nair R, Nair CM, Advani SH: All trans retinoic acid with low dose cytosine arabinoside in the treatment of myelodyplastic syndrome. Leuk Lymphoma 1997, 29:187-192.
41. 40 Simon D, Koehrle J, Reiners C, Boerner AR, Schmutzler C, Mainz K, et al.: Redifferentaition therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma. World J Surg 1998, 22:569-574.
42. 41 Grunwald F, Menzel C, Bender H, Palmedo H, Otte R, Fimmers R, et al.: Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med 1998, 39:1903-1906.
43. 42 Hoang-Vu C, Bull K, Schwartz I, Krause G, Schmutzler C, Aust G, et al.: Regulation of CD97 protein in thyroid carcinoma. J Clin Endocrinol Metab 1999, 84:1104-1109.
44. 43 Bischoff ED, Gottardis MM, Moon TE, Heyman RA, Lamph WW: Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma. Cancer Res 1998, 58:479-484.
45. 44 Budd GT, Adamson PC, Gupta M, Homayoun P, Sandstrom SK, Murphy RF, et al.: Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer. Clin Cancer Res 4:635-642.
46. 45 Sakukawa R, Murakami K, Ikeda T, Yamada Y, Saiki I: Effect of 4-[3,5-bis(trimethylsilyl) benzamido] benzoic acid (TAC-101) on the liver metastasis of colon 2-L5 carcinoma cells. Oncol Res 1998, 10:287-293.
47. 46 Shalinsky DR, Bischoff ED, Lamph WW, Zhang L, Boehm MF, Davies PJA, et al.: A novel retinoic acid receptor-selective retinoid, ALRT1550, has potent antitumor activity against human oral squamous carcinoma xenografts in nude mice. Cancer Res 1997, 57:162-168.
48. 47 Gottardis MM, Bischoff ED, Shirley MA, Wagoner MA, Lamph WW, Heyman RA: Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res 1996, 56:5566-5570.
49. 48 McCormick DL, Rao KVN, Steele VE, Lubet RA, Kelloff GJ, Bosland MC: Chemoprevention of rat prostate carcinogenesis by 9-cis-retinoic acid. Cancer Res 1999, 59:521-524.
50. 49 Muccio DD, Brouillette WJ, Breitman TR, Taimi M, Emanuel PD, Zhang X-K, et al.: Conformationally defined retinoic acid analogues. 4. Potential new agents for acute promyelocytic and juvenile myelomonocytic leukemias. J Med Chem 1998, 41:1679-1687.
51. 50 Takeshita A, Shibata Y, Shinjo K, Yanagi M, Tobita T, Ohnishi K, et al.: Successful treatment of relapse of acute promyelocytic leukemia with a new synthetic retinoid, Am80. Ann Intern Med 1996, 124:893-896.
52. 51 Lu X-P, Fanjul A, Picard N, Pfahl M, Rungta D, Nared-Hood K, et al.: Novel retinoid-related molecules as apoptosis inducers and effective inhibitors of human lung cancer cells in vivo. Nat Med 1997, 3:686-690.
53. 52 Mologni L, Ponzanelli I, Bresciani F, Sardiello G, Bergamaschi D, Gianni M, et al.: The novel synthetic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) causes apoptosis in acute promyelocytic leukemia cells through rapid activation of caspases. Blood 1999, 93:1045-1061.
54. 53 Li Y, Lin B, Agadir A, Liu R, Dawson MI, Reed JC, et al.: Molecular determinants of AHPN (CD437)-induced growth arrest and apoptosis in human lung cancer cell lines. Mol Cell Biol 1998, 4719-4731.
55. 54 Zou C-P, Kurie JM, Lotan D, Zou C-C, Hong WK, Lotan R: Higher potency of N-(4-hydroxyphenyl) retinamide than all-trans-retinoic acid in induction of apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res 4:1345-1355.
56. 55 Shalinsky DR, Bischoff ED, Gregory ML, Lamph WW, Heyman RA, Hayes JS, et al.: Enhanced antitumor efficacy of cisplatin in combination with ALRT1057 (9-cis retinoic acid) in human oral squamous carcinoma xenografts in nude mice. Clin Cancer Res 1996, 2:511-520.
57. 56 Anzano MA, Peer CW, Smith JM, Mullen LT, Shrader MW, Logsdon DL, et al.: Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. J Natl Cancer Inst 1996, 88:123-125.
58. 57 Schulman IG, Shao G, Heyman RA: Transactivation by retinoid X receptor-peroxisome proliferator-activated receptor γ (PPARγ) heterodimers: intermolecular synergy requires only the PPAR( hormone-dependent activation function. Mol Cell Biol 1998, 18:3483-3494.
59. 58 Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, et al.: Terminal differentiation of human breast cancer through PPARγ. Mol Cell 1998, 1:465-470.
60. 59 Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, et al.: Differentiation and reversal of malignant changes in colon cancer through PPARγ. Natl Med 1998, 4:1046-1052.
61. 60 Demetri GD, Fletcher CDM, Mueller E, Sarraf P, Naujoks R, Campbell N, et al.: Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A 1999, 96:3951-3956.
62. 61 Mukherjee R, Davies PJA, Crombie DL, Bischoff ED, Cesario RM, Jow L, et al.: Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 1997, 386:407-410.